Shilpa Medicare announces the approval of its IND - Nor Ursodeoxycholic Acid Tablets 500 mg, by the Subject Expert Committee of CDSCO. The Committee has further recommended grant of marketing ...
The spike in Shilpa Medicare's stock price came after the company announced the approval of its Investigational New Drug (IND ...
Schramm and colleagues [32] studied the utility of combined therapy with UDCA (500-750 mg/day), prednisolone (1 mg/kg per day initially, then tapering to 5-10 mg/day), and azathioprine (1-1.5 mg ...
The trials identified no serious adverse effects, and patients tolerated a daily dosage of 1500 mg for 24 weeks.
Non-alcoholic fatty liver disease (NAFLD) affects nearly 19 crore people in India and about a quarter of the world’s ...
UDCA has, therefore, been evaluated for the treatment of patients with PSC. Trials of UDCA at low doses (10–15 mg/kg per day and 17–20 mg/kg per day) have yielded inconclusive results in ...
Raichur: Shilpa Medicare Limited, recently announced that its Investigational New Drug (IND), Nor-Ursodeoxycholic Acid ...
Although UDCA was reported to improve liver enzyme levels in patients with PSC, the clinical benefits with respect to its effect on liver histology, symptoms, and radiologic appearance were not as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback